RISEDRONATO 35 mg Film-Coated Tablets

2. What you need to know before you take Risedronate Sodium Viatris

Do not takeRisedronate Sodium Viatris:

• If you are allergicto risedronate sodium or any of the other ingredients of this medicine (listed in section 6).
• If your doctor has told you that you have a disease called hypocalcemia(you have low levels of calcium in your blood).
• If you think you may be pregnant, are pregnantor are planning to become pregnant.
• If you are breast-feeding.
• If you have severe kidney disease.
• If you are under 18 years old.

Warnings and precautions

Consult your doctor or pharmacist before starting to take Risedronate Sodium Viatris:

• If you cannot stay upright (sitting or standing) for at least 30 minutes.
• If you have bone problems or mineral metabolism problems (e.g., vitamin D deficiency, parathyroid hormone disorders, both of which produce low calcium levels in the blood).

• If you have had problems with your esophagus (the tube that connects your mouth to your stomach) in the past. For example, you may have had pain or difficulty swallowing food, or you may have mentioned that you have Barrett's esophagus (a condition associated with changes in the cells that line the lower esophagus).
• If your doctor has told you that you are intolerant to certain sugars (such as lactose).
• If you have had or have pain, inflammation, or "numbness" of the jaw, jaw pain, or tooth loss.
• If you are undergoing dental treatment or are going to have dental surgery, inform your dentist that you are being treated with Risedronate Sodium Viatris.

Your doctor will advise you on what to do if you are taking Risedronate Sodium Viatris and have any of the problems mentioned above.

Children and adolescents

The use of risedronate sodium is not recommended in children and adolescents (under 18 years old) due to the lack of sufficient safety and efficacy data.

Other medicines and Risedronate Sodium Viatris

Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines.

Medicines that contain any of the following substances reduce the effect of Risedronate Sodium Viatris when taken at the same time:

• Calcium.
• Magnesium.
• Aluminum (e.g., some medicines for indigestion).
• Iron.

Take these medicines at least 30 minutes after taking Risedronate Sodium Viatris.

Risedronate Sodium Viatris with food and drinks

It is very important that you do NOT take Risedronate Sodium Viatris with food or drinks (other than tap water). In particular, do not take this medicine at the same time as dairy products (such as milk) as they contain calcium (see section 2, "Other medicines and Risedronate Sodium Viatris").

Take food and drinks (except tap water) at least 30 minutes after taking Risedronate Sodium Viatris.

Pregnancy and breast-feeding

DO NOT take Risedronate Sodium Viatris if you may be pregnant, are pregnant, or are planning to become pregnant (see section 2, "Do not take Risedronate Sodium Viatris"). The potential risk associated with the use of risedronate sodium (the active substance of Risedronate Sodium Viatris) in pregnant women is unknown.

DO NOT take Risedronate Sodium Viatris if you are breast-feeding (see section 2, "Do not take Risedronate Sodium Viatris").

Driving and using machines

It is not known if Risedronate Sodium Viatris affects the ability to drive or use machines.

Risedronate Sodium Viatris contains lactose

This medicine contains lactose. If your doctor has told you that you have an intolerance to certain sugars, consult with them before taking this medicine (see section 2, "Warnings and precautions").

3. How to take Risedronate Sodium Viatris

Posology

Follow the instructions for administration of Risedronate Sodium Viatris exactly as indicated by your doctor. Consult your doctor or pharmacist if you have any doubts.

The recommended dose is ONE tablet of Risedronate Sodium Viatris (35 mg of risedronate sodium) once a week.

Choose the day of the week that best suits your schedule. Each week, take the Risedronate Sodium Viatris tablet on the chosen day.

To facilitate taking the tablet on the same day each week, there are boxes on the packaging. Mark the day of the week you have chosen to take the Risedronate Sodium Viatris tablet. Also, write down the dates on which you will take the tablet.

When to take your Risedronate Sodium Viatris tablet:

Take the risedronate tablet at least 30 minutes before the first food, drink of the day (except in the case that this drink is tap water) or other medicine of the day.

How to take your Risedronate Sodium Viatris tablet:

• Take the tablet while standing or sitting uprightto avoid stomach upset.
• Swallow the tabletwith at least one glass(120 ml) of tap water.
• Swallow the tablet whole(do not suck or chew the tablet).
• Do not lie down for at least 30 minutesafter taking the tablet.

Your doctor will tell you if you should take calcium and vitamin D supplements if you are not getting enough in your diet.

If you take more Risedronate Sodium Viatris than you should

If you or someone else has taken more tablets of Risedronate Sodium Viatris than prescribed, drink a full glass of milkand go to the doctor.

In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, telephone 91 562 04 20, indicating the medicine and the amount taken.

If you forget to take Risedronate Sodium Viatris

If you have forgotten to take the tablet on the chosen day, take it on the day you remember.

Then take one tablet once a week, on the day you normally take the tablet.

DO NOT take a double dose to make up for forgotten doses.

If you stop taking Risedronate Sodium Viatris

If you stop taking the treatment, you may start to lose bone mass. Please talk to your doctor before stopping treatment.

If you have any other questions about the use of this medicine, ask your doctor or pharmacist.

4. Possible side effects

Like all medicines, Risedronate Sodium Viatris can cause side effects, although not everybody gets them.

Stop treatment with Risedronate Sodium Viatris and inform your doctor immediatelyif you experience any of the following:

• Symptoms of a severe allergic reaction such as:
• • Swelling of the face, tongue, or throat.
  • Difficulty swallowing.
  • Hives and difficulty breathing.
• Severe skin reactions that can include blisters on the skin.

Tell your doctor immediatelyif you experience any of the following side effects:

• Inflammation of the eyes, usually with pain, redness, and sensitivity to light.
• Jaw bone necrosis (osteonecrosis) associated with delayed healing and infection, often after a tooth extraction (see section 2, "Warnings and precautions").
• Symptoms in the esophagus such as pain and difficulty swallowing, chest pain, and heartburn or worsening of heartburn.

However, in clinical studies, the side effects that were observed were generally mild and did not cause the patient to stop treatment.

Common side effects(may affect up to 1 in 10 people):

Indigestion, nausea, stomach pain, upset stomach or discomfort, constipation, feeling full, abdominal distension, diarrhea.

Pain in the bones, muscles, or joints.

Headache.

Uncommon side effects(may affect up to 1 in 100 people):

Inflammation or ulceration of the esophagus (the tube that connects the mouth to the stomach) causing difficulty and pain when swallowing (see also section 2, "Warnings and precautions"), inflammation of the stomach and duodenum (intestine where the stomach empties).

Inflammation of the colored part of the eye (iris) (red eyes with possible changes in vision).

Rare side effects(may affect up to 1 in 1,000 people):

Inflammation of the tongue (swollen, red, possibly painful), narrowing of the esophagus (the tube that connects the mouth to the stomach).

Abnormal liver tests have been reported, which can only be diagnosed with a blood test.

Very rare side effects(may affect up to 1 in 10,000 people):

Talk to your doctor if you have ear pain, ear discharge, and/or an ear infection. These could be signs of damage to the bones of the ear.

During post-marketing experience, the following side effects have been reported (frequency not known):

Allergic reactions such as hives (hives), skin rash, swelling of the face, lips, tongue, and/or throat, difficulty swallowing or breathing. Severe skin reactions, including blisters under the skin, inflammation of small blood vessels, characterized by palpable red spots on the skin (leukocytoclastic vasculitis), a serious disease called Stevens-Johnson syndrome (SJS), with blisters on the skin, mouth, eyes, and other mucous membranes of the body (genital); a serious disease called Toxic Epidermal Necrolysis (TEN), which causes a red rash on many parts of the body and/or loss of the outer layer of the skin.

Hair loss. Allergic reactions (hypersensitivity). Serious liver disorders, especially if being treated with other medicines known to cause liver problems. Inflammation of the eye that causes pain and redness.

Rarely, at the start of treatment, a slight decrease in phosphate and calcium levels in the blood has been observed in some patients. These changes are usually small and do not cause symptoms.

Atypical fractures of the thigh bone (femur) can occur rarely, especially in patients on long-term treatment for osteoporosis. Inform your doctor if you notice pain, weakness, or discomfort in the thigh, hip, or groin, as these may be early symptoms of a possible fracture of the femur.

If you experience any side effect, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet.

Reporting of side effects:

If you experience any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly through the Spanish Medicines Monitoring System for Human Use: https://www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medicine.

5. Storage of Risedronate Sodium Viatris

Keep out of the reach and sight of children.

This medicine does not require any special storage conditions.

Do not use this medicine after the expiry date which is stated on the blister and packaging after EXP. The expiry date is the last day of the month indicated.

Medicines should not be disposed of via wastewater or household waste. Place the packaging and any unused medicine in the SIGRE collection point at your pharmacy. If you have any doubts, ask your pharmacist how to dispose of the packaging and any unused medicine. This will help protect the environment.

6. Contents of the pack and other information

Composition ofRisedronate Sodium Viatris

• The active substance is risedronate sodium. Each tablet contains 35 mg of risedronate sodium (equivalent to 32.5 mg of risedronic acid).
• The other ingredients (excipients) are:

Core of the tablet: pregelatinized corn starch, microcrystalline cellulose, crospovidone, magnesium stearate.

Coating of the tablet: hypromellose, lactose monohydrate, titanium dioxide (E171), macrogol 4000.

Appearance of the product and packaging

Risedronate Sodium Viatris are film-coated tablets, biconvex, round, white, with a diameter of 11.2 mm, 5.0 mm thick, and with "35" engraved on one side.

This medicine is presented in blisters that contain 4, 12 film-coated tablets and in a calendar blister of 4 film-coated tablets.

Not all pack sizes may be marketed.

Marketing authorization holder:

Viatris Limited

Damastown Industrial Park

Mulhuddart, Dublin 15

Dublin

Ireland

Manufacturer:

McDermott Laboratories Ltd. t/a Gerard Laboratories

35/36 Baldoyle Industrial Estate,

Grange Road, Dublin 13

Ireland

Or

Pharmathen International S.A.

Sapes Industrial Park

Block 5, 69300 Rodopi,

Greece

Or

Pharmathen, S.A.

6, Dervenakion str.

153 51 Pallini, Attiki,

Greece

Or

Mylan Hungary Kft.

Mylan Utca 1

Komárom, 2900

Hungary

You can request more information about this medicine by contacting the local representative of the marketing authorization holder:

Viatris Pharmaceuticals, S.L.U.

C/ General Aranaz, 86

28027 - Madrid

Spain

This medicine is authorized in the Member States of the European Economic Area under the following names:

Denmark Vionate Mylan film-coated tablets 35 mg

Spain Risedronate Sodium Viatris 35 mg film-coated tablets EFG

Italy Risedronate Mylan 35mg film-coated tablets

Portugal Vicendrolin

United Kingdom Risedronate Sodium 35mg film-coated tablets

Date of last revision of this leaflet:February 2016

Detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/